Literature DB >> 29863387

Influence of tiagabine maintenance on cannabis effects and related behaviors in daily cannabis users.

Michael J Wesley1, Philip M Westgate2, William W Stoops1, Thomas H Kelly1, Lon R Hays3, Joshua A Lile1.   

Abstract

No medications are approved for cannabis use disorder (CUD). Gamma-aminobutyric acid (GABA) reuptake is modulated by cannabinoid (CB) receptor agonists, and there are shared effects between CB agonists and the GABA reuptake inhibitor tiagabine. This overlapping neuropharmacology suggested that tiagabine might be useful for CUD. The study determined the ability of tiagabine maintenance to reduce cannabis self-administration using a placebo-controlled, double-blind, counterbalanced, within-subjects design. Nontreatment-seeking daily cannabis users (N = 12; 3 female, 9 male) completed two 12-day outpatient maintenance phases (0 or 12 mg of tiagabine/day). Each phase consisted of a safety session, 7 maintenance days, and 4 experimental sessions. During experimental sessions, maintenance continued and participants completed two 2-day blocks of sampling and self-administration sessions to determine the reinforcing effects of smoked cannabis (0% and 5.9% Δ9-tetrahydrocannabinol). Naturalistic cannabis use, the subjective, performance and physiological response to cannabis, as well as side effects, sleep quality, craving, other self-reported substance use, and observer ratings were also measured. Cannabis functioned as a reinforcer and produced prototypical effects (e.g., increased heart rate and ratings of "high"), but tiagabine generally did not impact the effects of cannabis, or alter naturalistic use. Furthermore, tiagabine produced small, but significant, increases on 2 subscales of a Marijuana Craving Questionnaire, and reductions in both the amount of time slept in the past 24 hr and ratings of positive mood upon awakening. These human laboratory results from a sample of nontreatment-seeking cannabis users do not support the potential efficacy of 12 mg of tiagabine as a stand-alone pharmacotherapy for CUD. (PsycINFO Database Record (c) 2018 APA, all rights reserved).

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29863387      PMCID: PMC5990026          DOI: 10.1037/pha0000180

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  39 in total

1.  Transdermal nicotine maintenance attenuates the subjective and reinforcing effects of intravenous nicotine, but not cocaine or caffeine, in cigarette-smoking stimulant abusers.

Authors:  Bai-Fang X Sobel; Stacey C Sigmon; Roland R Griffiths
Journal:  Neuropsychopharmacology       Date:  2004-05       Impact factor: 7.853

Review 2.  The role of human drug self-administration procedures in the development of medications.

Authors:  S D Comer; J B Ashworth; R W Foltin; C E Johanson; J P Zacny; S L Walsh
Journal:  Drug Alcohol Depend       Date:  2008-04-24       Impact factor: 4.492

3.  A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults.

Authors:  Barbara J Mason; Rebecca Crean; Vivian Goodell; John M Light; Susan Quello; Farhad Shadan; Kimberly Buffkins; Mark Kyle; Murali Adusumalli; Adnan Begovic; Santosh Rao
Journal:  Neuropsychopharmacology       Date:  2012-02-29       Impact factor: 7.853

Review 4.  Neurochemical regulation of sleep.

Authors:  Axel Steiger
Journal:  J Psychiatr Res       Date:  2006-06-13       Impact factor: 4.791

5.  An open-label comparison of nabilone and gabapentin as adjuvant therapy or monotherapy in the management of neuropathic pain in patients with peripheral neuropathy.

Authors:  Jennifer A Bestard; Cory C Toth
Journal:  Pain Pract       Date:  2010-11-18       Impact factor: 3.183

6.  The time course and significance of cannabis withdrawal.

Authors:  Alan J Budney; Brent A Moore; Ryan G Vandrey; John R Hughes
Journal:  J Abnorm Psychol       Date:  2003-08

7.  The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users.

Authors:  Ryan Vandrey; Maxine L Stitzer; Miriam Z Mintzer; Marilyn A Huestis; Jeannie A Murray; Dayong Lee
Journal:  Drug Alcohol Depend       Date:  2012-08-22       Impact factor: 4.492

8.  Identifying new cannabis use with urine creatinine-normalized THCCOOH concentrations and time intervals between specimen collections.

Authors:  Michael L Smith; Allan J Barnes; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2009-05       Impact factor: 3.367

Review 9.  The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees?

Authors:  G Rosenberg
Journal:  Cell Mol Life Sci       Date:  2007-08       Impact factor: 9.261

Review 10.  Pharmacotherapy for cannabis dependence: how close are we?

Authors:  Ryan Vandrey; Margaret Haney
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.